Investing Profile

Robert Nelsen

VCInvestorAngel
Co-founder and a Managing Director of ARCH Venture Partners
Photo of Robert Nelsen, Managing Director at ARCH Venture Partners
cb
ARCH Venture Partners Managing Director
$50K - $150.0M
$75.0M
90
$635.8M
CompanyStageDateRound SizeTotal Raised
Be Biopharma
Series UnknownOct 2024$82M
Series BApr 2022$130M
$260M
Co-investors: Steven Gillis (ARCH Venture Partners), Jason Rhodes (Atlas Venture)
City Therapeutics
Series AOct 2024$140M
$140M
Co-investors: Ari Nowacek (ARCH Venture Partners)
Stability AI
Series UnknownJun 2024$80M
$210M
£89M
Co-investors: Colin Bryant (New Enterprise Associates (NEA)), Gaurav Gupta (Lightspeed Venture Partners), Effie Epstein (Sound Ventures), Guy Oseary (Sound Ventures), Ashton Kutcher (Sound Ventures), Chris Denny-Brown (O'Shaughnessy Ventures), Walter Kortschak (Summit Partners), Jim O'Shaughnessy (O'Shaughnessy Ventures), Eric Schmidt (Innovation Endeavors), Dana Settle (Greycroft), Mei Z.
Vilya
Series AJun 2024$21M
Series AAug 2022$50M
$71M
Co-investors: Greg Yap (Menlo Ventures), Steven Gillis (ARCH Venture Partners)
Gameto
Series BMay 2024$33M
Series AJan 2022$20M
$73M
Co-investors: Dylan Morris (Insight Partners), Dan Rose (Coatue), Maryanna Saenko (Future Ventures), Steve Jurvetson (Future Ventures), Laura Stoppel (RA Capital), Jack Abraham (Atomic), Dusan Perovic (Two Sigma Ventures), Peter Kolchinsky (RA Capital), Anne Wojcicki
Xaira Therapeutics
Series AApr 2024$1B
$1B
Co-investors: Scott Gottlieb (New Enterprise Associates (NEA)), Vikram Bajaj (Foresite Capital)
Seaport Therapeutics
Series AApr 2024$100M
$330M
Co-investors: Brett Zbar (General Atlantic), James Healy (Sofinnova Investments)
Moonwalk Biosciences
Series AJan 2024$57M
$57M